Celltrion has announced that it completed the second biosimilar application for its monoclonal antibody infliximab on August 8, 2014. Click here for a Jones Day Commentary on the new biosimilar application process.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.










